The North America Allergy Immunotherapy Market would witness market growth of 8.1% CAGR during the forecast period (2023-2030).
There are three primary categories of allergy immunotherapy products currently in use: sublingual allergy immunotherapy (SLIT), subcutaneous allergy immunotherapy (SCIT)/injection, and oral allergy immunotherapy. Among them, SLIT offers therapy without injections instead of taking medications for allergies. The United States Food & Drug Administration (FDA) has approved tablets used in the SLIT treatment to treat allergies brought on by grass pollen, ragweed, and dust mites. However, SLIT only treats one particular allergen and does not prevent people from becoming allergic to other things.
It offers SCIT treatment a benefit because it concurrently delays the onset of asthma and other allergies. SCIT is thought to be the most effective type of allergy immunotherapy. The increasing demand for efficient combating techniques is projected to propel the market on a healthy growth trajectory as individuals worldwide become more sensitive to various allergens.
Due to the rising incidence of allergies, the rising desire for individualized medication, and the creation of novel and cutting-edge allergy immunotherapy solutions, the market has seen substantial expansion in recent years. Additionally, sublingual immunotherapy (SLIT)'s growing popularity supports market expansion. In this increasingly recent method of allergy immunotherapy, allergens are given sublingually rather than systemically.
According to the Canadian government, 850,000 children under 14 and more than 3.8 million adults in Canada suffer from asthma. The third-most prevalent chronic illness in Canada is asthma. Allergic asthma, which was more prevalent in male patients and was less frequently appropriately diagnosed at admission or had required prior hospitalization, is connected to the younger average age. Between 2010 and 2018, 379 individuals died in Mexican hospitals, at a mortality rate of 4.32 per 1000 hospital admissions. The market in this region will grow due to the rise in allergic asthma cases. The high prevalence of asthma in the region indicates the growth prospects for regional market.
The US market dominated the North America Allergy Immunotherapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $616.9 million by 2030. The Canada market is estimated to witness a CAGR of 10.6% during (2023 - 2030). Additionally, The Mexico market would showcase a CAGR of 9.6% during (2023 - 2030).
Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Treatment Type, the market is segmented into Subcutaneous Immunotherapy (SCIT), and Sublingual Immunotherapy (SLIT) (Tablets, and Drops). Based on Allergy Type, the market is segmented into Allergic Rhinitis, Allergic Asthma, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Allergy Immunotherapy Market is Projected to reach USD 2.9 Billion by 2030, at a CAGR of 8.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc. (Mylan N.V.), Merck KGaA , NIOX Group plc , DMS Imaging SA, Adamis Pharmaceuticals Corporation, Stallergenes Greer International AG (B-Flexion), Allergy Therapeutics plc , DBV Technologies S.A., HAL Allergy B.V. (Droege International Group AG.), LETI Pharma, S.L.U.
By Distribution Channel
By Treatment Type
By Allergy Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 